Risk Assessment of Maternal Neurologic Complications During Pregnancy

Abstract

Neurologic complications during pregnancy, though relatively uncommon, pose significant risks to both maternal and fetal health. Timely identification and risk stratification are essential for optimal management. This review synthesizes recent evidence, emphasizing epidemiology, pathophysiology, risk factors, clinical manifestations, diagnosis, management, emerging therapies, and guideline-based recommendations for maternal neurologic disorders in pregnancy, providing practical insights for clinicians.

Introduction

Pregnancy induces a spectrum of physiological changes that can precipitate or exacerbate neurologic disorders. The intersection of maternal neurologic complications with obstetric care demands a nuanced understanding of disease mechanisms, risk assessment, and evidence-based management. While some neurologic events are directly related to pregnancy, others represent exacerbations of preexisting conditions. The ability to distinguish between these scenarios and apply guideline-driven interventions is vital for optimizing maternal and fetal outcomes.

Epidemiology / Disease Burden

Neurologic complications in pregnancy, including cerebrovascular events, seizures, demyelinating diseases, and peripheral neuropathies, affect an estimated 0.1–2% of pregnancies globally. Stroke remains the leading cause of maternal morbidity and mortality from neurologic etiologies, with the incidence increasing due to maternal age and prevalence of vascular risk factors. Eclampsia accounts for a significant proportion of maternal seizures, while migraine is the most common chronic neurologic disorder during pregnancy. Regional and socioeconomic disparities further influence disease burden, with higher rates observed in resource-limited settings due to suboptimal prenatal care and delayed intervention.

Pathophysiology

Pregnancy induces profound hemodynamic, hormonal, and coagulative changes that alter neurologic risk profiles. Hypercoagulability, increased blood volume, and vascular permeability elevate the risk for thrombotic and hemorrhagic strokes. Endothelial dysfunction, especially in preeclampsia, contributes to blood-brain barrier disruption and cerebral edema. Hormonal fluctuations can precipitate migraine or epilepsy exacerbations. Autoimmune modulation during pregnancy influences the course of disorders such as multiple sclerosis, often reducing relapse rates but increasing postpartum. Understanding these mechanisms underpins risk assessment and targeted intervention strategies.

Risk Factors

Key risk factors for maternal neurologic complications include advanced maternal age, chronic hypertension, preeclampsia/eclampsia, diabetes mellitus, obesity, thrombophilia, prior neurologic disease, and autoimmune disorders. Family history, smoking, and substance use further elevate risk. Certain complications, such as cerebral venous sinus thrombosis, are more likely in the presence of inherited or acquired thrombophilias. The postpartum period, particularly the first six weeks, is associated with heightened risk for stroke and seizures due to abrupt hemodynamic and hormonal shifts. Stratifying risk based on clinical and laboratory data enables preventive strategies and tailored surveillance.

Clinical Features

Presentation varies by disorder but often includes headache, visual disturbances, altered mental status, focal neurologic deficits, and seizures. Stroke typically presents with sudden-onset focal deficits, while eclampsia manifests as tonic-clonic seizures in the context of hypertension and proteinuria. Demyelinating disorders may cause sensory, motor, or visual symptoms, often with a relapsing-remitting pattern. Early recognition of subtle signs, such as persistent headache or transient ischemic attacks, is critical, as delays in diagnosis can result in irreversible deficits or mortality.

Diagnosis

Diagnostic evaluation requires a multidisciplinary approach. Neuroimaging, preferably MRI without gadolinium, is the cornerstone for suspected stroke, demyelination, or mass lesions. CT is reserved for acute hemorrhage or when MRI is contraindicated. Laboratory testing includes complete blood count, coagulation profile, renal and hepatic panels, and evaluation for thrombophilia and autoimmune markers. Lumbar puncture may aid in the diagnosis of central nervous system infections or inflammatory conditions. Fetal monitoring is essential when maternal neurologic compromise is detected to assess fetal well-being.

Treatment & Management

Management of maternal neurologic complications is individualized, balancing maternal benefit and fetal safety. Acute ischemic stroke management may involve thrombolysis or thrombectomy, with careful risk-benefit assessment due to pregnancy-related bleeding risks. Eclampsia mandates prompt magnesium sulfate administration and blood pressure control. Seizure disorders are managed with antiepileptic drugs, preferably those with established safety profiles in pregnancy (e.g., lamotrigine, levetiracetam). Migraine is managed with non-pharmacologic measures and, when necessary, acetaminophen or beta-blockers. Multidisciplinary care, including neurology, obstetrics, anesthesia, and neonatology, is paramount for optimizing outcomes.

Recent Advances / Emerging Therapies

Recent research has refined risk stratification tools for predicting stroke and eclampsia in pregnancy, integrating clinical, radiologic, and laboratory data. Novel oral anticoagulants remain generally contraindicated, but selective use of low molecular weight heparin for thromboprophylaxis has expanded. Monoclonal antibodies for demyelinating diseases show promise, although data in pregnancy remain limited. Advances in neuroimaging and biomarker discovery are improving early detection of high-risk patients, enabling preemptive intervention. Ongoing clinical trials are evaluating the safety and efficacy of new antiepileptics and migraine therapies in pregnant populations.

Guideline Recommendations

Professional bodies such as the American College of Obstetricians and Gynecologists (ACOG), American Academy of Neurology (AAN), and European Stroke Organization provide consensus-driven guidelines for managing neurologic disorders in pregnancy. Recommendations emphasize preconception counseling, risk factor modification, early recognition, and individualized therapy. Use of neuroimaging is endorsed for suspected acute events, with preference for MRI. Anticoagulation protocols for thrombotic risk, magnesium sulfate for preeclampsia/eclampsia, and careful selection of antiepileptics are standard. Postpartum surveillance and multidisciplinary follow-up are integral to reducing recurrent risk.

Conclusion

Maternal neurologic complications during pregnancy, though infrequent, require vigilant risk assessment and interdisciplinary management to reduce morbidity and mortality. Advances in diagnostic modalities, risk stratification, and therapeutic options are enhancing outcomes, but continued research and guideline refinement are needed. Clinicians should maintain a high index of suspicion in at-risk populations, apply evidence-based protocols, and prioritize both maternal and fetal safety in therapeutic decision-making.